Sernova Cell Pouch: implantable islet-transplant scaffold: review notes

Outcome: Added critical supplementalportal-vein islet confounding disclosed by sponsorSep12,2024; firstcohort insulinindependence is not pouch-alone efficacy. Removed unrelatedVertex/stemcelltrialrelationships. Corrected direct item relationships; shared class or background is insufficient.

Registry: NCT03513939. Endpoint reviewed: To assess the safety of the Cell Pouch following implantation, and islet transplantation, by evaluating the incidence and severity of adverse events (AEs) determined to be probable or highly probable to the Cell Pouch (365 days ±14 days). Eligibility reviewed: Age 18 Years to 65 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Additional source access: Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device.; Sponsor primary report explicitly describing supplemental portal-vein transplants. Specific limit: Accessible primary mouse study is preclinical only. Human results are sponsor interim data; supplemental intraportal grafts prevent attributing cohortA insulin independence to the pouch alone. Latest company financial guidance was not independently re-audited here.